HeartBeam, Inc. (BEAT)
| Market Cap | 51.75M -12.3% |
| Revenue (ttm) | n/a |
| Net Income | -20.23M |
| EPS | -0.56 |
| Shares Out | 53.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 665,307 |
| Open | 1.0100 |
| Previous Close | 1.0400 |
| Day's Range | 0.9596 - 1.0200 |
| 52-Week Range | 0.5400 - 4.0000 |
| Beta | -0.87 |
| Analysts | Strong Buy |
| Price Target | 4.88 (+405.7%) |
| Earnings Date | May 13, 2026 |
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BEAT stock is "Strong Buy." The 12-month stock price target is $4.88, which is an increase of 405.70% from the latest price.
News
HeartBeam price target lowered to $5 from $8 at Benchmark
Benchmark lowered the firm’s price target on HeartBeam (BEAT) to $5 from $8 and keeps a Speculative Buy rating on the shares after “a solid update” provided with Q1 results.
HeartBeam Earnings Call Transcript: Q1 2026
Achieved key milestones in commercialization, clinical validation, and product development, including flagship accounts in four major geographies and a strategic AI partnership. Q1 2026 saw a 19% year-over-year reduction in cash burn, with a strengthened balance sheet and funding runway into 2027.
HeartBeam reports Q1 EPS (12c) vs. (18c) last year
“In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we’ve consistently discussed over the last several quarters. ...
HeartBeam Reports First Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results.
HeartBeam initiates pilot study of first on-demand 12-lead ECG patch
HeartBeam (BEAT) announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two…
HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic.
HeartBeam announces commercial agreement with Atelier Health
HeartBeam (BEAT) announced a commercial agreement with Atelier Health, a concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based A...
HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice.
HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time.
HeartBeam downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital downgraded HeartBeam (BEAT) to Hold from Buy without a price target following the company’s’ capital raise. The “deal size and terms represent a strategic misstep,” the analyst…
HeartBeam Announces Closing of $10 Million Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of $10 Million Public Offering of Common Stock.
HeartBeam 12.5M share Spot Secondary priced at 80c
Titan Partners acted as sole book running manager for the offering.
HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock.
HeartBeam announces common stock offering, no amount given
HeartBeam (BEAT) announced that it is commencing an underwritten public offering of shares of its common stock. All of the securities to be sold in the proposed offering will be…
HeartBeam Announces Proposed Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Proposed Public Offering of Common Stock.
HeartBeam initiated with a Buy at B. Riley
B. Riley initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free…
HeartBeam initiated with a Buy at Stifel
Stifel initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free device…
HeartBeam initiated with a Buy at D. Boral Capital
D. Boral Capital initiated coverage of HeartBeam (BEAT) with a Buy rating and $5 price target The company’s novel ambulatory electrocardiogram platform aims to replicate the diagnostic capability of a...
HeartBeam Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
A novel at-home 12-lead ECG platform is launching with a subscription model targeting concierge cardiology, leveraging strong physician and patient demand. The company is expanding into ambulatory monitoring and AI-driven cardiac care, supported by clinical studies and strategic partnerships.
HeartBeam Earnings Call Transcript: Q4 2025
FDA clearance for 12-lead ECG software enabled commercial launch and partnerships, with strong demand in concierge cardiology. Net loss narrowed, cash use declined, and 2026 will focus on scaling adoption, clinical studies, and AI development.
HeartBeam reports Q4 EPS (62c) vs (73c) last year
“The fourth quarter of 2025 and early 2026 were transformational for HeartBeam (BEAT), culminating in the FDA 510(k) Clearance for our 12-Lead ECG synthesis software. With that clearance, we are…
HeartBeam Reports Fourth Quarter and Full Year 2025 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Fourth Quarter and Full Year 2025 Results.
HeartBeam announces AI pact with Icahn School of Medicine at Mount Sinai
HeartBeam (BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithm...
HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home.
HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch
SANTA CLARA--(BUSINESS WIRE)--HeartBeam to Attend Investor and Industry Conferences in March.